Differences in the Clinical and Hematological Characteristics of COVID-19 Patients with and without Type 2 Diabetes

Table 4

Laboratory findings of the coagulation function of patients with and without T2D infected with COVID-19.

Variables	Normal range	NDM group ()			T2D group ()			value
		Median (IQR)	Increased No. (%)	Decreased No. (%)	Median (IQR)	Increased No. (%)	Decreased No. (%)
Prothrombin time (sec)	9-13	11.55	2 (5.13%)	0 (0.00%)	11.71	0 (0.00%)	0 (0.00%)	0.82
PT activity (%)	75-135	93.60	0 (0.00%)	8 (20.51%)	89.74	0 (0.00%)	1 (3.33%)	0.54
PT international normalized ratio	0.76-1.24	0.98	3 (7.69%)	4 (10.26%)	1.41	2 (6.67%)	5 (16.67%)	0.24
Activated partial thrombin time (sec)	25-31.3	27.83	4 (10.26%)	1 (2.56%)	26.96	3 (10.0%)	0 (25%)	0.16
Thrombin time (sec)	14-21	18.02	2 (5.13%)	0 (0.00%)	18.21	1 (3.33%)	0 (0.00%)	0.52
Fibrinogen (g/L)	2-4	4.26	15 (38.46%)	0 (0.00%)	4.05	16 (53.30%)	1 (3.33%)	0.75
D-dimer (mg/L)	0-0.55	2.20	24 (61.54%)	0 (0.00%)	3.19	22 (73.33%)	0 (0.00%)	0.17
Fibrinogen degradation products (mg/L)	0-5	7.56	14 (35.90%)	0 (0.00%)	10.25	8 (26.67%)	0 (0.00%)	0.36
Antithrombin III activity (%)	80-120	89.29	1 (2.56%)	8 (20.51%)	86.86	0 (0.00%)	6 (20.0%)	0.72